Chemotherapy Induced Nausea and Vomiting. Enabling better treatment, ensuring better quality of life. Is a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets. Nausea and vomiting is a common complication of both surgery and chemotherapy. Acacia Pharma has generated a pipeline of product opportunities addressing a range of supportive .

Developing disease modifying Alkaline Phosphatase therapeutics for Acute Kidney Injury, Inflammatory Bowel Disease and Hypophosphatasia. Recently, the company started a Phase II trial in patient.

In the battle against antibiotic. Stevenage, UK 20 March 2017 Auspherix Limited, the anti-infectives company meeting the urgent.

Unrivalled efficiency in lignocellulosic conversion. World-class engineering and scientific capabilities. BioGasol is a leading supplier of advanced sugar extraction systems. BioGasol also operates the Pentocrobe.

BioScience Managers Translation Fund I. Asia Pacific Healthcare Fund II. BioScience Managers Ventures Fund I. Downing FOUR Healthcare Share Class. Investing in innovative science and technology to transform healthcare. Adherium Names Tim Houchin Vice President of Sales. AVITA Medical Announces FDA Approval of Expansion of RECELL Compassionate Use Program in Life Threatening Injuries.

Brandon Capital Partners manages the MRCF Collaboration, providing seed and venture capital investment to support the development and international growth of Australian and New Zealand life science companies. We work collaboratively with entrepreneurs to demonstrate the benefit of their technology, thereby creating value for them, their teams and our investors. Prof Darren Kelly, CEO, OccuRx.

Crescendo Biologics Appoints Dani Bach as Non-Executive Director. Crescendo Biologics to present poster at AACR Annual Meeting 2018, Chicago. Crescendo Biologics is discovering and developing potent and highly differentiated Humabody. Therapeutics with a focus on key cancer indications with a high unmet need. Technology, we are building.

GI Therapies was established in Melbourne in 2012 to commercialise innovative technology the treat gastrointestinal motility disorders including chronic constipation, irritable bowel syndrome with constipation and gastroparesis. The initial product, Rhythm IC.

The Brewery, London EC1. Nominations are now open! Click here to nominate. The 2018 Awards will take place on Thursday 14 June. Click here for information on ways to be involved. Details of the 2017 winners. News, video and photos from the 2017 Dinner. Sign up for email alerts.

Mission is the world leader in DUB drug discovery and development. A rich pipeline of first-in-class therapeutics that selectively target specific disease-associated DUBs. Mission has a collaborative, science-driven culture with strong links to key academic and research centers.